|
tsx:zyme
|
126235
|
Apr 21st, 2024 12:00AM
|
Zymeworks Inc.
|
25K
|
283.00
|
Open
|
|
Apr 21st, 2024 09:08AM
|
Apr 21st, 2024 09:08AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 20th, 2024 12:00AM
|
Zymeworks Inc.
|
25K
|
283.00
|
Open
|
|
Apr 20th, 2024 08:05AM
|
Apr 21st, 2024 03:23AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 19th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
283.00
|
Open
|
|
Apr 19th, 2024 10:39AM
|
Apr 19th, 2024 10:39AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 18th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
283.00
|
Open
|
|
Apr 18th, 2024 09:17AM
|
Apr 19th, 2024 07:03AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 17th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
284.00
|
Open
|
|
Apr 17th, 2024 10:39AM
|
Apr 17th, 2024 09:19PM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 16th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
284.00
|
Open
|
|
Apr 16th, 2024 08:15AM
|
Apr 16th, 2024 05:36PM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 15th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
284.00
|
Open
|
|
Apr 15th, 2024 10:59AM
|
Apr 16th, 2024 05:00AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 14th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
283.00
|
Open
|
|
Apr 14th, 2024 07:00AM
|
Apr 14th, 2024 07:00AM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 13th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
283.00
|
Open
|
|
Apr 13th, 2024 05:53AM
|
Apr 13th, 2024 05:54PM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|
|
tsx:zyme
|
126235
|
Apr 12th, 2024 12:00AM
|
Zymeworks Inc.
|
24K
|
283.00
|
Open
|
|
Apr 12th, 2024 06:07AM
|
Apr 12th, 2024 03:03PM
|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
|
Open
|
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
|
Open
|
540 - 1385 West 8th Ave
|
Vancouver
|
BC
|
CA
|
V6H 3V9
|
|
Zymeworks
|
|
|